K2M Funds Its Focus On The Complex Spine With IPO
This article was originally published in Start Up
Executive Summary
The 10-year-old spine firm initiated its initial public offering this month, transforming from the largest private spine device firm to another public player in a highly competitive market. CEO Eric Major says K2M’s focus on complex spinal deformities will help distinguish it from the pack.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q2 2014
Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of life sciences companies.
Mega-Deals In Orthopedics: Size Matters
With the surprise announcement that Zimmer, the number three player, will acquire Biomet, the number five player, in a transaction valued at $13 billion, a transformation in the orthopedic industry is underway. Most of the major orthopedic manufacturers are primed with a war chest of cash to make acquisitions for future growth, and as health care reform unfolds, companies are positioning themselves to compete in a changing world where “bigger is better.”
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.